2 not yet recruiting, 1 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow ProGen. Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus PG-102(MG12), Dulaglutide - Type 2 Diabetes | Phase 2 | Not yet recruiting | ProGen. Co., Ltd. | 60 | 2026-10-01 | 2026-07-01 |
| Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus PG-102, Placebo, Semaglutide - Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Not yet recruiting | ProGen. Co., Ltd. | 80 | 2026-01-01 | 2025-09-23 |
| Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes PG-102, Placebo - Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus | Phase 2 | Active not recruiting | ProGen. Co., Ltd. | 144 | 2024-12-05 | 2025-07-11 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants. PG-102(MG12), Placebo - Healthy, Overweight | Phase 1 | Completed | ProGen. Co., Ltd. | 102 | 2024-03-04 | 2025-05-06 |
Diabetes Mellitus, Type 2 (3) · Overweight (1)
dulaglutide (1) · semaglutide (1)
South Korea (2) · Australia (1)
Hyuk-Sang Kwon, MD (1) · In Kyung Jeong, MD (1) · Jae Hyeon Kim, MD (1) · Jae-Heon Kang, MD (1) · Jang Won Son, MD (1) · Jun Hwa Hong, MD (1) · Kyu Chang Won, MD (1) · Kyung Wan Min, MD (1) · Nan Hee Kim, MD (1) · Sang Youl Rhee, MD (1) · Seung-Hwan Lee, MD (1) · Seunghoon Han, MD (1) · Sin Gon Kim, MD (1) · Soo Lim, MD (1) · Yong-Ho Lee, MD (1)